BRPI0512864B8 - composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição - Google Patents

composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição

Info

Publication number
BRPI0512864B8
BRPI0512864B8 BRPI0512864A BRPI0512864A BRPI0512864B8 BR PI0512864 B8 BRPI0512864 B8 BR PI0512864B8 BR PI0512864 A BRPI0512864 A BR PI0512864A BR PI0512864 A BRPI0512864 A BR PI0512864A BR PI0512864 B8 BRPI0512864 B8 BR PI0512864B8
Authority
BR
Brazil
Prior art keywords
omega
fatty acid
composition
preparing
ophthalmic composition
Prior art date
Application number
BRPI0512864A
Other languages
English (en)
Portuguese (pt)
Inventor
Schaumberg Debra
Molock Frank
Osborn Lorenz Kathy
Copper Lenora
Dana Reza
Rashid Saadia
Mahadevan Shiv
Original Assignee
Johnson & Johnson Vision Care
Schepens Eye Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512864(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson & Johnson Vision Care, Schepens Eye Res filed Critical Johnson & Johnson Vision Care
Publication of BRPI0512864A publication Critical patent/BRPI0512864A/pt
Publication of BRPI0512864B1 publication Critical patent/BRPI0512864B1/pt
Publication of BRPI0512864B8 publication Critical patent/BRPI0512864B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0512864A 2004-07-01 2005-06-30 composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição BRPI0512864B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58451404P 2004-07-01 2004-07-01
US60/584,514 2004-07-01
PCT/US2005/023113 WO2006007510A1 (en) 2004-07-01 2005-06-30 Compositions and methods for treating eye disorders and conditions

Publications (3)

Publication Number Publication Date
BRPI0512864A BRPI0512864A (pt) 2008-04-08
BRPI0512864B1 BRPI0512864B1 (pt) 2021-04-27
BRPI0512864B8 true BRPI0512864B8 (pt) 2021-05-25

Family

ID=35784207

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512864A BRPI0512864B8 (pt) 2004-07-01 2005-06-30 composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição

Country Status (15)

Country Link
US (2) US20060009522A1 (enExample)
EP (1) EP1781278B2 (enExample)
JP (1) JP2008505177A (enExample)
KR (1) KR20070040381A (enExample)
CN (1) CN101043884A (enExample)
AU (1) AU2005262392A1 (enExample)
BR (1) BRPI0512864B8 (enExample)
CA (1) CA2572344A1 (enExample)
IL (1) IL180342A0 (enExample)
MX (1) MX2007000208A (enExample)
NO (1) NO20070561L (enExample)
NZ (1) NZ552481A (enExample)
RU (1) RU2007103835A (enExample)
WO (1) WO2006007510A1 (enExample)
ZA (1) ZA200700918B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
CA2584415A1 (en) * 2004-10-19 2006-04-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Topical treatment with ngf and dha in damaged corneas
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
HRP20171691T1 (hr) 2009-06-05 2017-12-15 Allergan, Inc. Umjetne suze i njihova upotreba u terapiji
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20130245119A1 (en) * 2010-11-19 2013-09-19 Keio University Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
WO2012145119A2 (en) * 2011-04-17 2012-10-26 Michael Gurin Low inflammatory blended oils
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (pt) 2011-05-25 2017-05-05 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20160310456A1 (en) * 2013-03-12 2016-10-27 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
EP2755647B1 (en) * 2011-09-12 2015-08-19 Georgiou, Tassos Use of omega fatty acids for treating disease
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
EP2664330A1 (de) 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
US20160051503A1 (en) * 2012-08-31 2016-02-25 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US8673325B1 (en) * 2012-09-06 2014-03-18 Dignity Sciences Limited Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2014222417B2 (en) 2013-02-26 2017-09-07 Belkin Vision Ltd. System for glaucoma treatment
ES2687094T3 (es) 2013-07-23 2018-10-23 Novaliq Gmbh Composiciones estabilizadas de anticuerpos
US20150080329A1 (en) * 2013-09-19 2015-03-19 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
JP2017516823A (ja) 2014-06-04 2017-06-22 ディグニティ サイエンシス リミテッド Ｄｇｌａを含む薬学的組成物及びその使用
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
EP3229908A4 (en) * 2014-12-12 2018-06-27 Schepens Eye Research Institute. Inc. Gdnf induction for the treatment of retinal disorders
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
CA3008774C (en) 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN106963728A (zh) * 2016-01-13 2017-07-21 汤欣 一种二十二碳六烯酸结膜下注射液的制备方法及其应用
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
ES2965883T3 (es) 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
ES2982698T3 (es) * 2020-01-23 2024-10-17 Visufarma S P A Composición oftálmica para el tratamiento de la enfermedad del ojo seco
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437014A (en) * 1890-09-23 Swing
US3572913A (en) * 1969-02-03 1971-03-30 Boylston Res Ass Comprehensive support for ophthalmic examination apparatus and instruments
US4180308A (en) * 1972-10-02 1979-12-25 Syntex (Usa) Inc. Contact lens
US4401372A (en) * 1972-10-02 1983-08-30 Syntex (U.S.A.) Inc. Contact lens
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
DE2309440A1 (de) * 1973-02-26 1974-09-05 Katz Verfahren zum isolieren von lysozym
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4313355A (en) * 1978-02-06 1982-02-02 Syntex (U.S.A.) Inc. Method and apparatus for manufacturing plastic lenses
US4202226A (en) * 1978-02-06 1980-05-13 SyntexLaboratories, Inc. Method and apparatus for manufacturing plastic lenses
US4338419A (en) * 1979-02-09 1982-07-06 Syntex (U.S.A.) Inc. Process for treatment of hydrogel lens with thiols
US4379864A (en) * 1979-02-09 1983-04-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4543371A (en) * 1981-03-05 1985-09-24 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US5145686A (en) * 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
EP0092076B1 (fr) 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
US4678698A (en) * 1983-04-12 1987-07-07 Minnesota Mining And Manufacturing Company Contact lens cleaning article
US4533399A (en) * 1983-04-12 1985-08-06 Minnesota Mining And Manufacturing Company Contact lens cleaning method
US4622258A (en) * 1983-04-12 1986-11-11 Minnesota Mining And Manufacturing Company Contact lens cleaning article
JPS6158539A (ja) * 1984-08-29 1986-03-25 Nisshin Oil Mills Ltd:The スナツク様菓子の製造法
US4613380A (en) * 1985-04-01 1986-09-23 Dow Corning Corporation Method for removing lipid deposits from contact lenses
US5484432A (en) * 1985-09-27 1996-01-16 Laser Biotech, Inc. Collagen treatment apparatus
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5240702A (en) * 1986-05-15 1993-08-31 Emory University Method of treating stroke
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8710780D0 (en) 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
CA1263270A (en) * 1987-08-19 1989-11-28 Bruce J. Holub Animal feed supplement
US5225374A (en) * 1988-05-13 1993-07-06 The United States Of America As Represented By The Secretary Of The Navy Method of fabricating a receptor-based sensor
US5111221A (en) * 1988-05-13 1992-05-05 United States Of America As Represented By The Secretary Of The Navy Receptor-based sensor
US4923700A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Artificial tear suspension
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5278142A (en) * 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5206298A (en) * 1989-12-19 1993-04-27 Tomei Sangyo Kabushiki Kaisha Graft copolymer, solution containing the graft copolymer for treating contact lens, and method of treating contact lens with the solution and making hydrophilic lens surface
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ES2084722T3 (es) * 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
US5167323A (en) * 1990-08-09 1992-12-01 Tomei Sangyo Co., Ltd. Lens treating device for treating contact lens
US5181604A (en) * 1990-09-14 1993-01-26 Tomei Sangyo Co., Ltd. Contact lens holder and treating device
US5203337A (en) * 1991-05-08 1993-04-20 Brigham And Women's Hospital, Inc. Coronary artery imaging system
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
JPH06122627A (ja) * 1992-10-13 1994-05-06 Sagami Chem Res Center 抗アレルギー点眼液
US5378488A (en) * 1993-06-10 1995-01-03 Abbott Laboratories Aseptic processing of infant formula
ES2114305T3 (es) * 1993-12-29 1998-05-16 Bausch & Lomb Composicion a base de glucidos y procedimiento de limpieza y de desinfeccion de lentes de contacto.
US6060644A (en) * 1994-03-24 2000-05-09 Iowa State University Research Foundation, Inc. Isolation and use of cuticular lipid genes
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6113894A (en) * 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
CN1226816A (zh) * 1996-08-02 1999-08-25 普拉姆开米制品股份有限公司 用于人体皮肤的清洁、保护或改善皮肤状况的水包油型乳剂
EP0883811A1 (en) * 1996-09-20 1998-12-16 Atherogenics Inc. Diagnostics for and mediators of inflammatory disorders
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
JPH10218760A (ja) 1997-02-04 1998-08-18 Nobel Igaku Kenkyusho:Kk ドライアイ治療用の微量油添加目薬
AU6631298A (en) * 1997-03-03 1998-09-22 Adcock Ingram Limited A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
DE69839054T2 (de) * 1997-09-03 2009-01-15 The Regents Of The University Of California, Oakland Biomimetrische materialien vom hydrogel-typ
US6475784B1 (en) * 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
AU754064B2 (en) 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
US6346594B1 (en) * 1998-09-21 2002-02-12 Menicon Co., Ltd. Ocular lens material and process for producing same
EP1156809B1 (en) * 1999-03-01 2005-12-07 Vista Scientific LLC Mucin containing ophthalmic preparations
US6429194B1 (en) * 1999-03-01 2002-08-06 Vista Scientific Llc Mucin containing ophthalmic preparation
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
AUPQ228199A0 (en) 1999-08-18 1999-09-09 Sly, Anthony William Ophthalmic fluid
EP1408930A1 (de) * 1999-10-20 2004-04-21 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US6286955B1 (en) * 1999-12-15 2001-09-11 Tetsuya Sakai Biocompatible lens, and method of producing the same
US6344047B1 (en) * 2000-02-02 2002-02-05 Eagle Vision Instrument for inserting a punctum plug and method for manufacturing the instrument
US6533415B2 (en) * 2000-03-21 2003-03-18 Menicon Co., Ltd. Ocular lens material having hydrophilic surface and process for preparing the same
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
AU2001283068A1 (en) * 2000-08-01 2002-02-13 Ocular Research Of Boston, Inc. Visual discomfort relief
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6667047B2 (en) * 2001-07-27 2003-12-23 International Flute Technologies Ltd Ultra-stable composition comprising moringa oil and its derivatives and uses thereof
WO2003018049A2 (en) * 2001-08-23 2003-03-06 Westgate Biological Limited Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
US20040076691A1 (en) 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
US7378444B2 (en) * 2002-06-17 2008-05-27 Brigham And Women's Hospital, Inc. Analogues of lipid mediators derived from omega-3 PUFAs and methods of use
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP2005008570A (ja) * 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface

Also Published As

Publication number Publication date
KR20070040381A (ko) 2007-04-16
JP2008505177A (ja) 2008-02-21
EP1781278A4 (en) 2009-09-02
US20060009522A1 (en) 2006-01-12
ZA200700918B (en) 2008-10-29
MX2007000208A (es) 2007-08-07
NZ552481A (en) 2008-12-24
EP1781278B1 (en) 2016-08-10
BRPI0512864A (pt) 2008-04-08
EP1781278B2 (en) 2019-10-16
BRPI0512864B1 (pt) 2021-04-27
NO20070561L (no) 2007-03-30
AU2005262392A1 (en) 2006-01-19
US20080153909A1 (en) 2008-06-26
RU2007103835A (ru) 2008-08-10
IL180342A0 (en) 2007-07-04
CN101043884A (zh) 2007-09-26
WO2006007510A1 (en) 2006-01-19
EP1781278A1 (en) 2007-05-09
CA2572344A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
BRPI0512864B8 (pt) composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
BRPI0413197A (pt) cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
CL2009000696A1 (es) Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras.
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
ECSP066669A (es) Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos
DK1259243T3 (da) Bupropion-metabolitter, fremgangsmåde til deres fremstilling samt anvendelse deraf
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BRPI0414096A (pt) sistema lipìdico e métodos de uso
WO2006030439A3 (en) Compositions and methods for inducing hair growth
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
DOP2022000031A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
DK1201244T3 (da) Phosphatidyl-L-serin og phosphatidinsyre til behandling af depression og stresstilstande
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.